We sought kinase domain (KD) mutations at the start of treatment with dasatinib in 46
chronic myeloid leukemia (CML) patients resistant to or intolerant of imatinib. We identified …

Chronic myeloid leukemia (CML) is a myeloproliferative disease caused due to translocation
between chromosome 9 and 22 leading to a chimeric gene product known as Bcr-Abl. Bcr …

Since the introduction of imatinib mesylate (IM) for the treatment of chronic myeloid leukemia
(CML), impressive clinical responses have been observed in the majority of patients in …

Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …

Chronic Myeloid Leukemia (CML) is a disease arising in stem cells expressing the BCR-ABL
oncogenic tyrosine kinase that transforms one Hematopoietic stem/progenitor Cell into a …

Background Chronic myeloid leukemia is successfully managed by imatinib therapy, but the
question remains whether treatment must be administered indefinitely. Imatinib …

Chronic myeloid leukemia chronic phase (CML-CP) CD34+ cells contain numerous DNA
double-strand breaks whose unfaithful repair may contribute to chromosomal instability and …

Although Imatinib has transformed the treatment of chronic myeloid leukemia (CML), it is not
curative due to the persistence of resistant cells that can regenerate the disease. We have …

Although imatinib mesylate has revolutionized the treatment of chronic myeloid leukaemia
(CML), resistance to the drug, manifesting as relapse after an initial response or persistence …

Background Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-
line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of …